Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada. The presentation will begin at 11:35 a.m. P.T. / 2:35 p.m. E.T.
聖地亞哥，2024年5月8日（GLOBE NEWSWIRE）——Turnstone Biologics Corp.（“Turnstone” 或 “公司”）（納斯達克股票代碼：TSBX）是一家臨床階段的生物技術公司，通過開創精選的腫瘤浸潤淋巴細胞（精選TIL）療法，開發差異化方法來治療和治癒實體瘤患者，今天宣佈，工商管理碩士，博士薩米·法拉總裁兼首席執行官將出席即將於2024年5月15日星期三在內華達州拉斯維加斯舉行的美國銀行證券醫療保健會議。演講將於太平洋時間上午 11:35 /美國東部時間下午 2:35 開始
To access a live webcast of the presentation, please visit the Events page in the Investors section of the Company's website at . A webcast replay will be available for a limited period.
要觀看演講的網絡直播，請訪問公司網站 “投資者” 部分的 “活動” 頁面，網址爲。網絡直播重播將在有限的時間內提供。
Members of Turnstone's senior management will also be available for one-on-one meetings during the conference. Interested investors should contact their Bank of America Securities representative for further information.
會議期間，Turnstone的高級管理層成員也將參加一對一的會議。感興趣的投資者應聯繫其美國銀行證券代表以獲取更多信息。
About Turnstone
關於 Turnstone
Turnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Turnstone's next-generation TIL therapy is based upon the identification, selection and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone's most advanced program, TIDAL-01, is currently being evaluated in multiple Phase 1 studies in patients with colorectal cancer, breast cancer, head and neck cancer, uveal melanoma, and cutaneous melanoma. The Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit , and follow us on LinkedIn.
Turnstone Biologics是一家臨床階段的生物技術公司，通過開創精選的腫瘤浸潤淋巴細胞（精選TIL）療法，開發了一種差異化的治療和治癒實體瘤患者的方法。Turnstone的下一代TIL療法基於對最有效的腫瘤反應性T細胞（即精選TIL）的鑑定、選擇和擴展，旨在克服第一代散裝TIL的侷限性，這種侷限性僅在有限的腫瘤類型中表現出客觀的反應。Turnstone最先進的項目 TIDAL-01 目前正在對結直腸癌、乳腺癌、頭頸癌、葡萄膜黑色素瘤和皮膚黑色素瘤患者的多項1期研究進行評估。該公司還積極推進其臨床前研發項目，包括 TIDAL-02、其下一個精選 TIL 項目以及 TIDAL-01 和病毒免疫療法組合計劃。有關Turnstone的更多信息，請訪問並在LinkedIn上關注我們。
Contact
聯繫我們
Ahmed Aneizi
Investor Relations
Turnstone Biologics
(347) 897-5988
ahmed.aneizi@turnstonebio.com
艾哈邁德·阿內齊
投資者關係
Turnstone 生物製劑
(347) 897-5988
ahmed.aneizi@turnstonebio.com